Disc is seeking accelerated approval and priority review of its NDA submission FDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 ...
Disc Medicine is well-capitalized, with over $800M in cash, ensuring operational runway through 2029 regardless of bitopertin's launch success. Bitopertin’s NDA is submitted, aiming for accelerated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results